EUCTR2009-011160-11-FR进行中（未招募）1 期
A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q - GFM-Aza-Rev-09
Groupe Francophone des Myélodysplasies (GFM)0 个研究点开始时间: 2009年7月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria
- •1.Age = 18 years
- •2.Must understand and voluntarily sign an informed consent form
- •3.Must Especially in the case of AML: Patient considered ineligible for intensive chemotherapy due to age, cardiac contraindication to anthracyclines, comorbidities, previous failure of intensive chemotherapy, or patient willing to avoid intensive chemotherapy
- •4.Must be able to adhere to the study visit schedule and other protocol requirements
- •5.Prior Thalidomid allowed
- •6.Documented diagnosis of MDS, or CMML with WBC < 13,000/mm3 that meets IPSS criteria for intermediate-2 or high-risk disease, or AML
- •7.with an associated del 5q[31] (the deleted chromosomal region must include 5q[31]), with or without additional cytogenetic abnormalities
- •8.Female subjects of chilbearing potential* must :
- •- Understand the study drug is expected to have a teratogenic risk. -
- •- Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/ml on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. The test should ensure the subject is not pregnant when she starts treatment.
- •- Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization. These pregnancy tests should be performed on the day of the study visit or in the 3 days prior to the study visit. This requirement also applies to women of childbearing potential who practice complete and continued abstinence.
- •- Agree to use, and to be able to comply with, effective contraception without interruption, 4 weeks before starting study drug throughout the entire duration study drug therapy (including doses interruptions) and for 3 months after the end of the study drug therapy even if she has amenorrhoea. This applies unless the subject commits to absolute and continuous abstinence confirmed on a monthly basis, to avoid pregnancy for the duration of study.
- •If not established on effective contraception, the female subject must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.
- •Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide and dexamethasone, combined oral contraceptive pills are not recommended. If a female subject is currently using combined oral contraception, the patient should switch to one of the effective methods listed above. The risk of venous thromboembolism continues for 4 to 6 weeks after discontinuing combined oral contraception. The efficacy of contraceptive steroids may be reduced during co-treatment with dexamethasone.
- •Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia .
- •Copper-releasing intrauterine devices are generally not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with neutropenia or thrombocytopenia.
- •- Understand that even if she has amenorrhea, she must follow all the advice on effective contraception.
- •- She understands
排除标准
- •Exclusion criteria
- •1.Pregnant or lactating females.
- •2.Proliferative (WBC = 13,000/mL) Chronic Myelomonocytic Leukaemia(CMML)
- •3.Prior = grade-2 NCI CTCAE (v 3.0) allergic reaction to thalidomide.
- •4.Prior desquamating (blistering) rash while taking thalidomide.
- •5.Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for = 3 years.
- •6.Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days, with the exception of hydroxyurea in case of high WBC counts
- •7.Less than 6 months since prior allogeneic bone marrow transplantation.
- •8.Less than 3 months since prior autologous bone marrow or stem cell transplantation.
- •9.Recombinant human erythropoietin (rHuEPO) therapy received within 28 days.
- •10.Known HIV-1 positivity.
- •11.Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he or she participates in the study.
- •12.Any of the following laboratory abnormalities:
- •Creatinine Clearance < 50 mL/min
- •Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 3.0 x up-per limit of normal
- •Serum total bilirubin > 2 ULN except unconjugated hyperbilirubinemia related toMDS.
- •13.ubjects with = grade-2 neuropathy
研究者
相似试验
进行中（未招募）
不适用
A phase ii study of the efficacy and safety of lenalidomide combined to escalating doses of chemotherapy in intermediate-2-or high risk MDS and AML with del 5 q31 - GFM-chimio-Rev-08Myelodysplastic Syndrome(MDS) / Acute Myeloid Leukemia(AML)MedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2008-006032-36-FRGroupe Francophone des Myélodysplasies (GFM)
进行中（未招募）
1 期
enalidomide, subcutaneous bortezomib, and dexamethasone treatment for multiple myelomaEUCTR2013-005008-32-IECancer Trials Ireland42
进行中（未招募）
1 期
A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failureRecurrent unresectable or metastatic cervix carcinomaMedDRA version: 21.1Level: PTClassification code 10008344Term: Cervix carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002184-97-FRCentre François Baclesse57
进行中（未招募）
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2020-004964-25-ITAffibody AB110
进行中（未招募）
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2020-004964-25-ESAffibody AB110